Related Experiment Video
Updated: Jun 17, 2026
07:51
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Chemogenomic profiling predicts antifungal synergies
Gregor Jansen1, Anna Y Lee, Elias Epp
1Department of Biochemistry, Faculty of Medicine, McGill University, Montréal, Québec, Canada. gregor.jansen@mcgill.ca
Molecular Systems Biology
|December 24, 2009
Summary
A new bioinformatics approach predicts synergistic drug combinations for treating systemic fungal infections in immunocompromised patients. This method identifies effective multi-agent antifungal therapies by analyzing compound profiles, improving treatment outcomes.
Area of Science:
- Medical Mycology
- Bioinformatics
- Computational Biology
Background:
- Immunocompromised populations (due to chemotherapy, HIV, organ transplant rejection) face high risks of systemic fungal infections.
- Single-agent antifungal therapies often fail due to drug resistance, necessitating alternative strategies like combination therapies.
Purpose of the Study:
- To develop and validate a bioinformatics-driven method for predicting synergistic compound combinations against fungal pathogens.
- To identify novel synergistic antifungal agents for use in combination therapies.
Main Methods:
- Utilized chemogenomic profiles to identify compounds with statistically significant similarity to fluconazole profiles.
- Employed a bioinformatics approach to predict compound synergy for combinatorial antifungal therapies.
- Experimentally validated predicted synergistic compound combinations in Saccharomyces cerevisiae and Candida albicans.
Main Results:
- The bioinformatics approach successfully predicted synergistic compound combinations.
- Identified compounds that demonstrated synergy with fluconazole and with each other.
- Experimental validation confirmed the predicted synergy in both model yeast and a pathogenic fungus.
Conclusions:
- The developed bioinformatics method accurately predicts compound synergy for antifungal drug discovery.
- This approach can accelerate the development of effective multi-agent antifungal therapies for immunocompromised individuals.
- Enables the creation of novel combinatorial antifungal treatments to combat drug resistance.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...